Formycon AG (FYB) Price & Analysis

Compare

30 Followers

FYB Stock Chart & Stats

€20.20

€0.60(0.99%)

At close: Jan 09 4:00 PM EST

€20.20

€0.60(0.99%)

Day’s Range― - ―

52-Week Range€19.18 - €64.40

Previous CloseN/A

Volume3.47K

Average Volume (3M)24.96K

Market Cap

€373.78M

Enterprise Value€477.53M

Total Cash (Recent Filing)€27.29M

Total Debt (Recent Filing)€10.21M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.07

Shares Outstanding17,672,928

10 Day Avg. Volume17,772

30 Day Avg. Volume24,962

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.01

Price to Sales (P/S)13.33

P/FCF Ratio-17.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€43.80

Price Target Upside116.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe first ranibizumab biosimilar in pre-filled syringe commercially launched in Europe, starting in France with additional countries to follow, potentially leading to higher royalty revenue streams to Bioeq and Formycon.

Regulatory ApprovalsFYB203 has received approval from both the European Commission and the FDA, indicating strong regulatory support for the product.

Strategic AlliancesFormycon entered an exclusive license agreement granting Valorum the commercial rights to FYB203 in the U.S. and Canada, enhancing its market presence.

Bears Say

Regulatory RisksThere are risks related to the failure of biosimilar candidates in clinical trials, securing regulatory approval, achieving commercial success, and potential dilution.

Formycon AG News

Formycon AG: Strategic Advancements and Market Opportunities Drive Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Formycon AG, with...

17d ago

Strategic Developments and Partnerships Boost Formycon AG’s Growth Prospects and Support Buy Rating

Formycon AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

1M ago

Formycon AG: Strategic Positioning and Promising Pipeline Justify Buy Rating and €48 Price Target

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Formycon AG today and set a price target...

2M ago

FYB Earnings this Week: How Will it Perform?

Formycon AG (FYB) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

Formycon AG’s FYB206 Study: A Potential Game Changer in Melanoma Treatment

Formycon AG (($DE:FYB)) announced an update on their ongoing clinical study. Formycon AG is conducting a clinical study...

4M ago

FYB

Formycon AG: Strategic Advancements and Expanding Partnerships Justify Buy Rating

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on FYB stock, giving a Buy rating today....

4M ago

Formycon AG: Strategic Financial Growth and Market Expansion Justify Buy Rating

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Formycon AG. The associated price target...

4M ago

Formycon AG’s FYB206 Study Termination: Market Implications

Formycon AG (($DE:FYB)) announced an update on their ongoing clinical study. Formycon AG’s recent clinical study aimed to...

4M ago

FYB

Formycon AG: Strategic Developments and Positive Outlook Justify Buy Rating Despite Revenue Shortfall

Formycon AG (FYB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

6M ago

Formycon AG: Strong Market Position and Growth Prospects Justify Buy Rating

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Formycon AG (FYB – Research Report)....

7M ago

FYB FAQ

What was Formycon AG’s price range in the past 12 months?

Formycon AG lowest stock price was €19.18 and its highest was €64.40 in the past 12 months.

What is Formycon AG’s market cap?

Formycon AG’s market cap is €373.78M.

When is Formycon AG’s upcoming earnings report date?

Formycon AG’s upcoming earnings report date is Nov 13, 2025 which is in 5 days.

How were Formycon AG’s earnings last quarter?

Formycon AG released its earnings results on Aug 13, 2025. The company reported -€3.07 earnings per share for the quarter, missing the consensus estimate of -€0.1 by -€2.97.

Is Formycon AG overvalued?

According to Wall Street analysts Formycon AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Formycon AG pay dividends?

Formycon AG does not currently pay dividends.

What is Formycon AG’s EPS estimate?

Formycon AG’s EPS estimate is -0.04.

How many shares outstanding does Formycon AG have?

Formycon AG has 17,672,928 shares outstanding.

What happened to Formycon AG’s price movement after its last earnings report?

Formycon AG reported an EPS of -€3.07 in its last earnings report, missing expectations of -€0.1. Following the earnings report the stock price went down -1.381%.

Which hedge fund is a major shareholder of Formycon AG?

Currently, no hedge funds are holding shares in DE:FYB

Formycon AG Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
€43.80 (116.83% Upside)

Technicals

Fundamentals

Return on Equity

-34.48%

Trailing 12-Months

Asset Growth

-21.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Formycon AG (FYB) Earnings & Revenues

Historic Earnings Reports

FYB Stock 12 Month Forecast

Average Price Target

€43.80

▲(116.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"€20","37":"€37","54":"€54","28.5":"€28.5","45.5":"€45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€43.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,28.5,37,45.5,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.9,24.138461538461538,26.376923076923077,28.615384615384613,30.853846153846153,33.09230769230769,35.33076923076923,37.56923076923077,39.80769230769231,42.04615384615384,44.284615384615385,46.52307692307692,48.761538461538464,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.9,23.584615384615383,25.269230769230766,26.95384615384615,28.638461538461534,30.32307692307692,32.00769230769231,33.69230769230769,35.37692307692308,37.06153846153846,38.746153846153845,40.43076923076923,42.11538461538461,{"y":43.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.9,22.52307692307692,23.146153846153844,23.769230769230766,24.392307692307693,25.015384615384615,25.638461538461538,26.26153846153846,26.884615384615383,27.50769230769231,28.130769230769232,28.753846153846155,29.376923076923077,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >